mProX™ Human GPC3 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human GPC3 Stable Cell Line (S01YF-1023-PY273). Click the button above to contact us or submit your feedback about this product.
Morgan Johnson (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Skyler Garcia (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Knockdown of GPC3 in Huh-7 cells.
The expression of GPC3 in Huh7 cells was assessed through Western blot analysis, with experiments being conducted in triplicate, and the results were expressed as mean values, demonstrating a significant difference (P < 0.01) compared to the control, while GAPDH was utilized as a loading control.
Ref: Miao, Hui-Lai, et al. "Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP." Journal of cellular biochemistry 114.3 (2013): 625-631.
Pubmed: 23060277
DOI: 10.1002/jcb.24404
Research Highlights
Lu, Li-Li. et al. "GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy." Cell biology and toxicology, 2023.
The present study examines the efficacy of GPC3-7-19-CAR-T cells, a novel chimeric antigen receptor (CAR)-T-cell therapy developed by the authors, in treating advanced hepatocellular carcinoma (HCC). Conventional GPC3-CAR-T cells have shown unsatisfactory clinical results in HCC, and the underlying mechanism remains unclear. The authors aim to elucidate the clinical potential of GPC3-7-19-CAR-T cells and investigate the mechanisms behind their antitumor effects. This innovative approach has the potential to significantly impact the treatment of advanced cancer.
Lu, Li-Li. et al. "GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy." Cell biology and toxicology, 2023.
Pubmed:
37853185
DOI:
10.1007/s10565-023-09821-w
Tavakoli Pirzaman, Ali. et al. "The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens." Technology in cancer research & treatment, 2023.
Oxaliplatin (cyclohexane-1,2-diamine; oxalate; platinum [2+]) is a third-generation chemotherapeutic drug with potent anticancer properties. It has been used in the treatment of various types of cancer, including colorectal cancer, breast cancer, lung cancer, bladder cancer, prostate cancer, and gastric cancer. However, despite its efficacy, the development of resistance to oxaliplatin poses a challenge in its therapeutic utility. This review examined the role of microRNAs, a subtype of small non-coding RNAs, in modulating oxaliplatin's response in gastrointestinal cancers. Furthermore, it discussed the potential of microRNA-based strategies in enhancing the sensitivity of cancer cells to oxaliplatin and reducing oxaliplatin-induced neuropathic pain.
Tavakoli Pirzaman, Ali. et al. "The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens." Technology in cancer research & treatment, 2023.
Pubmed:
37849311
DOI:
10.1177/15330338231206003
